On November 2, 2021 Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, reported the upcoming presentations by members of its management team at several industry and scientific conferences during November 2021 (Press release, ImmuneTune, NOV 2, 2021, View Source [SID1234594081]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are looking forward to presenting our platform of synthetic DNA vaccines to an audience of investors, pharma and biotech companies, and scientists and investigators," said Sijme Zeilemaker, CEO of Immunetune. "With our lead program NeoVAC, a personalized neoantigen cancer vaccine, moving towards the clinic in 2022, it is a great opportunity to showcase our unique differentiation and explore collaborations with leaders in this field."

Upcoming conferences:

Drug Discovery Strategic Summit, November 4 – 5, Amsterdam, the Netherlands

CEO Sijme Zeilemaker will be presenting on November 4th, 9:50 – 10:10 AM, on "Next-generation DNA vaccines targeting cancer and infectious diseases".

LSX Investival Showcase, November 8 – 15, Virtual / London, UK

CEO Sijme Zeilemaker will be participating virtually and in person on November 15th in London. Please reach out to [email protected] if you would like to set up a meeting within our scope of investors and pharma/biotech collaborations.

Festival of Biologics / World Immunotherapy Congress, November 9 – 11, Basel, Switzerland

CEO Sijme Zeilemaker will be presenting on November 9th, 5:50 – 6:10 PM, in the Innate & Adaptive Checkpoint Inhibition track on "Neoantigen cancer vaccines based on synthetic linear DNA with a pyroptotic adjuvant synergize with checkpoint inhibitors".

Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, November 10 – 14, Virtual / Washington, D.C., US

CSO Jeroen van Bergen will be presenting the poster titled "Personalized synthetic polyepitope DNA cancer vaccines encoding a novel pyroptotic adjuvant to generate effective anti-tumor T cell immunity". Abstracts can be accessed on the SITC (Free SITC Whitepaper) website once the conference begins on November 9th; posters will be presented on November 12 and 13.

On November 2, 2021 Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, reported that it will host a conference call and webcast on Tuesday, November 9, 2021 at 8:00 a.m. ET to report financial results for the third quarter ended September 30, 2021 and provide business updates (Press release, Mersana Therapeutics, NOV 2, 2021, https://ir.mersana.com/news-releases/news-release-details/mersana-therapeutics-host-conference-call-announcing-third-2 [SID1234594075]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 2116349. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.

On November 2, 2021 OncoSec Medical Incorporated (NASDAQ: ONCS) reported that it will host a conference call and webcast for investors and analysts on Friday, November 12 at 7:00 AM ET featuring key opinion leaders (KOLs) Matteo Carlino, MD, from Westmead and Blacktown Hospitals, Adil Daud, MD, from University of California San Francisco, Pablo Fernandez Peñas MD, PhD, FACD, from The University of Sydney, and Montaser Shaheen, MD, from the University of Arizona Cancer Center. The KOLs will discuss the clinical relevance of the updated KEYNOTE-695 data being presented in a poster at the SITC (Free SITC Whitepaper) 2021 Annual Meeting. Specifically, the KEYNOTE-695 clinical trial enrolled metastatic melanoma patients that are refractory to Immune Checkpoint Blockade, non-responders as defined by the Society of Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) recommendations.1

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Adil Daud, M.D., a Professor of Medicine at The University of California, San Francisco, Director of the Melanoma Clinical Research, remarked, "TAVO works by optimizing cellular uptake of DNA-based IL-12 in the tumor microenvironment, leading to local, sustained production of IL-12 in the tumor, where it matters. TAVO recruits and primes immune cancer-fighting cells in the tumor leading to systemic immune responses without systemic toxicity, and we look forward to the updated data at SITC (Free SITC Whitepaper) 2021 in this highly refractory patient population."

To register for the event, please click here.

1Kluger HM, Tawbi HA, Ascierto ML, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC (Free SITC Whitepaper) Immunotherapy Resistance Taskforce. Journal for ImmunoTherapy of Cancer 2020;8:e000398. doi:10.1136/ jitc-2019-000398

On November 2, 2021 MorphoSys AG reported Monjuvi(R) Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the upcoming Conference Call on November 11, 2021 (Press release, MorphoSys, NOV 2, 2021, View Source [SID1234594073])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announces that revenues from product sales of Monjuvi(R) (tafasitamab-cxix) in the U.S. amount to € 18.6 million (US$ 22 million) for the third quarter of 2021 and € 46.4 million (US$ 55.5 million) for the first nine months of 2021. Monjuvi(R) is being co-commercialized by Incyte and MorphoSys in the United States.

MorphoSys will publish its full results for the first nine months and third quarter 2021 on November 10, 2021 at 10:00pm CET (4:00pm EST).

MorphoSys’ Management Board will host a conference call and webcast on November 11, 2021 at 2:00pm CET (8:00am EST) to present the first nine months and third quarter financial results 2021 and provide a further outlook for 2021.

The conference call will start with a presentation by the Management Board followed by a Q&A session.

A live webcast and slides will be made available at the Media and Investors section under Conferences on MorphoSys’ website, www.morphosys.com.

On November 2, 2021 Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported that an article highlighting preclinical data from BT7480, a tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing CD137 (4-1BB), was published in the Journal for ImmunoTherapy of Cancer (JITC) (Press release, Bicycle Therapeutics, NOV 2, 2021, View Source [SID1234594072]). The article, titled "BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist (Bicycle TICA) induces tumor localized CD137 agonism" is available online via this link.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"CD137 is an important co-stimulatory receptor expressed on multiple components of the immune system. CD137 activation can drive anti-tumor immunity but activation outside of the tumor may give rise to toxicity. To that end, we have developed BT7480, a novel, first-in-class Nectin-4/CD137 Bicycle TICA, that activates CD137 only in the presence of Nectin-4 expressing tumor cells," said Nicholas Keen, Ph.D., Chief Scientific Officer of Bicycle Therapeutics. "The data published today in JITC describe BT7480’s ability to elicit rapid reprogramming of the tumor immune microenvironment, which leads to complete regressions and anti-tumor immunity with only intermittent drug exposure in syngeneic mouse tumor models. We believe this work supports the clinical investigation of BT7480 for the treatment of cancer, and we look forward to dosing the first patient in our Phase I/II clinical trial which we plan to commence by the end of this year."